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Imaging studies in drug-dependent subjects show reduced striatal dopamine D2/3 receptor
(DRD2/3) availability, and it is hypothesized that increasing DRD2/3 availability is a promising
strategy to treat drug dependence. We recently showed that rats treated for two weeks with
2 mg/kg/day varenicline (a partial agonist at α4β2 nicotinic acetylcholine receptors) showed
higher striatal DRD2/3 availability compared to control rats. The present study examined the
effects of lower varenicline doses as well as the duration of the effect after treatment
discontinuation. DRD2/3 availability in striatal areas was studied in 80 rats following two-week
treatment with 0.5, 1 or 2 mg/kg/day varenicline or vehicle and survival of the effects of
varenicline on DRD2/3 availability up to 2 weeks after treatment discontinuation using 123I-IBZM
storage phosphor imaging. For all varenicline doses, varenicline treated rats showed a
comparable significantly higher DRD2/3 availability in the ventral striatum of approximately
11% compared to control rats, while only the rats treated with 1 and 2 mg/kg/day dose showed
significantly higher DRD2/3 availability in the dorsal striatum by 12.5% and 13.2% compared to
control rats, respectively. Two weeks after discontinuation of the active treatment with 2 mg/
kg/day varenicline, DRD2/3 binding in ventral, but not dorsal, striatum was still significantly
higher (11.7%) compared to vehicle. Varenicline induces dose-dependent and sustained increases
in striatal DRD2/3 in rats, particularly in the ventral striatum. These observations suggest that
increased DRD2/3 availability may contribute to varenicline's efficacy for smoking cessation and
show promise for varenicline as a treatment of other types of drug dependence.
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206 C.L. Crunelle et al.1. Introduction a temperature- and humidity-controlled room under a 12/12 h lightA consistent finding in human imaging studies in drug
dependence, includingnicotinedependence, is a lower receptor
density of striatal dopamine (DA) D2/3 receptors (DRD2/3)
(Beukers et al., 2009; Fehr et al., 2008; Martinez et al., 2004).
For example, in cocaine-dependent patients, Martinez et al.
found a 15% reduction in striatal DRD2/3 availability compared
to healthy subjects (Martinez et al., 2004), a finding that was
replicated in another cohort (Martinez et al., 2009). In addition,
acute dopaminergic depletion induced by alpha-methyl-para-
tyrosine (AMPT) administration showed lower occupancy of
striatal DRD2/3 by endogenous dopamine. Therefore, reduction
inDRD2/3could not be attributed tohigher levels of endogenous
DA in the striatal regions of cocaine-dependent patients during
PET imaging (Martinez et al., 2009).
Varenicline is a registered aid for smoking cessation and
clinically results in reducedpleasurewhile smoking, decreased
craving, and an increased probability of long-term abstinence
(Cahill et al., 2008). Varenicline is a high affinity partial
agonist atα4β2 nicotinic acetylcholine receptors (nAChR)with
a much lower binding affinity for other nAChR subtypes at
which it either acts as a partial agonist (e.g. α3β4) or as a full
agonist (α7) (Mihalak et al., 2006; Rollema et al., 2007, 2010).
Interestingly, preclinical studies have shown that varenicline
indirectly interacts with the DAergic system and seems to
result in increased DRD2/3 availability in the striatum (for a
review, see Crunelle et al., 2010). Indeed, about one third of
α4β2 nAChRs are localized on DAergic cell bodies of the
mesolimbic DA reward circuitry (Zhou et al., 2003) and (β2-
containing) nAChRs are believed to modulate and enhance DA
cell firing in the ventral tegmental area (VTA), characteristic
for reward-related signaling (Dani, 2001; Reperant et al.,
2010; Rice andCragg, 2004; TangandDani, 2009).Moreover, in
a previous studyweobserved that rats treatedwith varenicline
(2 mg/kg/day injected for 14 consecutive days) showed a
significantly higher striatal DRD2/3 availability than control
rats (Crunelle et al., 2009). However, this experiment had
several limitations: it was performed with one relatively high
dose of varenicline and did not examine the sustained effects
of varenicline on DRD2/3 availability after discontinuation of
treatment. Together, these findings raise the possibility that
varenicline could also be an effective treatment for addictions
other than nicotine dependence (Chatterjee and Barlett,
2010; Crunelle et al., 2010; McKee et al., 2010), because
previous studies have suggested that upregulation of the
DRD2/3 is a promising strategy for the treatment of addiction
in general (Nader et al., 2006; Blum et al., 2008).
In the current study, we examined the effects of two-
week treatment with three doses of varenicline on DRD2/3
availability in striatal regions of rats and whether the effect
of two-week treatment with the highest dose of varenicline
on DRD2/3 availability was sustained in striatal regions up to
two weeks after the last injection with varenicline.2. Experimental procedures
2.1. Animals
Eighty male Wistar rats (Harlan, The Netherlands), weighing 250–
300 g at the start of the experiment, were housed in groups of five incycle (lights on at 07:00 am). Rats were given one week to
acclimatize before the experiments. Food and water were available
ad libitum and body weight was recorded daily throughout the
experiment. All experimental procedures were approved by the
Animal Ethics Committee (AMC, Amsterdam, The Netherlands).2.2. Dosing regimen
To assess the effects of several doses of varenicline on DRD2/3
availability, rats were randomized to varenicline or vehicle (0.9%
saline). Varenicline was administered subcutaneously (s.c.) twice
daily (BID), because of its short half-life of 4 h in rats (Obach et al.,
2006), at 8:00–9:00 am and 3:00–4:00 pm. Control rats (n=10) were
administered vehicle for 14 consecutive days, at times similar to
those of the varenicline administrations, twice per day. One day
after the last injection, ex-vivo measurement of DRD2/3 availability
was performed using storage phosphor imaging (Knol et al., 2008;
Crunelle et al., 2009).
The sustained effects of varenicline on DRD2/3 availability
after treatment discontinuation were studied in rats that were
randomized to either varenicline 2 mg/kg/day BID or vehicle BID
for 14 consecutive days. DRD2/3 availability was assessed using ex-
vivo storage phosphor imaging at one week and at two weeks after
the last injection with either varenicline or vehicle (n=10 and
n=10).2.3. Ex-vivo storage phosphor imaging
The imaging method used to assess DRD2/3 availability has been
described in detail before (Crunelle et al., 2009; Knol et al., 2008).
Briefly, rats were anesthetized and 0.20 ml±0.05 ml of the selective
DRD2/3 radiotracer 123I-IBZM (37.7 MBq±2.8 MBq) was given i.v.
through the tail vein. Ninety minutes after IBZM injection (Verhoeff
et al., 1993), brains were removed and sliced into 50 μm slices. Every
fourth brain slice was stored on phosphor imaging plates for 16 h±1 h.
Regions of interest (ROIs) were drawn around the left and right
striatum and the cerebellum (devoid of DRD2/3) for each rat according
to a standard rat brain atlas (Paxinos and Watson, 1986), as earlier
described (Crunelle et al., 2009). Subsequently, IBZM binding in ROIs
(expressed as photostimulated luminescence) was analyzed using AIDA
imaging software.
For both right and left dorsal striatum, 13 consecutive slices with
highest binding were selected for each rat. For the ventral striatum
(nucleus accumbens), twoconsecutive sliceswith thehighest binding for
both left and right hemispheres were selected. Non-specific bindingwas
determined by selecting nine consecutive slices of the cerebellum with
the highest binding. Ratios of striatal-to-cerebellar binding were then
calculated using the following equation:
left + rightð Þ striatum½ = 2
cerebellum
.
These ratios were interpreted as a measure for DRD2/3 availability.2.4. Study medication
Varenicline (7,8,9,10-tetrahydro- 6,10-methano-6H-pyrazino (2,3-h)
(3)-benzazepine) tartrate) was kindly provided by Pfizer Global
Research and Development (Groton, CT, USA), and dissolved in 0.9%
sodium chloride to obtain an injectable solution. In all experiments
doses are expressed as the active compound (base). Solutions were
made fresh twice a week, and were kept refrigerated during the
experiment. The radiotracer 123I-IBZM was commercially produced by
GE Healthcare (Eindhoven, The Netherlands) with a specific activity of
550 MBq/mol and a radiochemical purity of N95%. Anesthesia was
performed with a 2:1 mix of ketamine and xylazine.
Figure 1 Effects of 14 days s.c. varenicline treatment in rats
on 123I-IBZM binding ratios in the dorsal striatum (A) and the
ventral striatum (B) using ex-vivo storage phosphor imaging.
Bars represent striatal-to-cerebellar binding ratios expressed as
mean +/− SD. *pb0.05 vs vehicle-treatment.
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Data were analyzed with SPSS 17 (SPSS Inc, Chicago, IL, USA), using a
probability value of 0.05 as significant. All data were normally
distributed and a one-way ANOVA was used to assess between-group
differences. Post-hoc analyses were performed using independent
sample T-tests for non-repeated measures and assuming equal
variances. To assess differences between right and left striatum, a
dependent-sample T-test was used.
3. Results
Data from 4 rats were excluded from the analyses due to
premature death following anesthesia and 123I-IBZM injection
(2 rats) or due to data acquisition failures (2 rats).Since there were no differences between binding ratios in
left and right striatum (paired differences±SD: 0.01±0.09;
p=0.79 for the dorsal striatum, and 0.03±0.09; p=0.43 for the
ventral striatum) all data are presented as the mean binding
ratio of left and right sides. Furthermore, all data were
normally distributed (Shapiro–Wilk test; p=0.60–0.90).
3.1. Experiment 1: Effect of several doses of
varenicline on DRD2/3 availability
Rats treated with the lowest dose of varenicline (0.5 mg/kg/
day; n=9) showed a significant 11.1% higher binding ratio in the
ventral striatum compared to vehicle-treated rats (p=0.015;
95% CI=2.5%–19.7%, n=9), but no statistically significant
difference in binding ratios in the dorsal striatum (p=0.590;
NS) was found (Fig. 1). At 1 mg/kg/day, rats treated with
varenicline showed a significantly higher DRD2/3 availability by
11.1% in the ventral striatum (p=0.009; 95% CI=3.1%–19.1%,
n=10) and by 12.5% in the dorsal striatum (p=0.048; 95%
CI=0.2%–24.9%) compared to vehicle (n=9) (see Fig. 1). Finally,
rats treated with the highest dose of varenicline (2 mg/kg/day;
n=10) showed significant higher binding ratios in both ventral
striatum (11.1% increase; p=0.036, 95%CI: 0.8%–21.4%) and
dorsal striatum (13.2% increase; p=0.030, 95%CI: 1.4%–25.0%)
compared to vehicle-treated rats (n=9) (see Fig. 1).
3.2. Experiment 2: Sustained effects of varenicline
treatment on DRD2/3 availability
One week after discontinuation of treatment with 2 mg/kg/day
varenicline for 14 days, the increase in binding ratios was still
significantly higher in the ventral striatum (12.8% increase;
p=0.018; 95% CI: 2.5%–23.1%, n=9) compared to vehicle-
treatment one week after discontinuation of vehicle injections
(n=10), but not in the dorsal striatum (6.4% increase, p=0.287)
(see Fig. 2). Similar changes were observed one week later, i.e.
at two weeks after varenicline treatment, with statistically
higher binding ratios in the ventral striatum (11.7% increase;
p=0.015; 95% CI: 2.6%–20.8%, n=10), but not in the dorsal
striatum (8.2% increase, p=0.09) compared to vehicle-treat-
ment two weeks after discontinuation of vehicle injections
(n=9) (see Fig. 2).
4. Discussion
Rats treated with varenicline 2 mg/kg/day for 14 consecutive
days had significantly higher DRD2/3 availabilities in the dorsal
striatum (13.2%) and the ventral striatum (11.1%) compared to
vehicle-treated rats, which is a close replication of results
from a previous study using the same varenicline treatment
that found higher DRD2/3 availabilities of 14.7% and 13.9% in
dorsal and ventral striatum compared to controls, respectively
(Crunelle et al., 2009). The present study also examined the
effects of two lower doses of varenicline and found that one
day after 2-week treatment with 0.5 and 1 mg/kg/day
varenicline, DRD2/3 availability was higher in the ventral
striatum by 11.1% for both doses compared to controls, and
that only the 1 mg/kg/day dose showed a significantly higher
DRD2/3 availability in the dorsal striatum by 12.5% compared
to controls. In addition, up to two weeks after the last
Figure 2 Effects of post-treatment time of varenicline in rats
(treated for 14 days, s.c.) on 123I-IBZM binding ratios in the
dorsal striatum (A) and ventral striatum (B) using ex-vivo storage
phosphor imaging. Bars represent striatal-to-cerebellar binding
ratios and are represented as mean +/− SD. *pb0.05 vs vehicle.
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varenicline, DRD2/3 availability was still significantly higher
than controls in the ventral striatum (12.8%), but not in the
dorsal striatum.
The present design and results do not allow us to advocate
a specific mechanism of action by which varenicline
increases striatal DRD2/3 availability in the rat striatum.
Varenicline acts at α4β2 nAChRs and has a partial agonist
effect in the absence of nicotine, reducing withdrawal during
a quit attempt, and an antagonist effect when actively
smoking, blocking the rewarding effects of nicotine by
competing for nAChRs (Rollema et al., 2007). It is known
that about one third of α4β2 nAChRs in the brain are
localized on DAergic cell bodies of the mesostriatal neurons
(Zhou et al., 2003) and that β2-containing nAChRs are
believed to enhance DA cell firing and DA release (Dani,
2001; Reperant et al., 2010; Rice and Cragg, 2004; Tang andDani, 2009). Preclinical studies have indeed shown that
acute administration of both nicotine and varenicline
increases DA release and turnover with a smaller maximal
effect in varenicline (~150% increase) compared to nicotine
(~180%) (Rollema et al., 2007; Ericson et al., 2009). Recently
it was demonstrated that this effect of varenicline, similar to
nicotine-induced mesolimbic DA increases, is most likely
mediated via α4β2 nAChRs in the ventral tegmental area
(VTA), which contains dopaminergic neurons that project
predominantly to the ventral striatum (Reperant et al.,
2010). It is, however, unlikely that varenicline-evoked DA
release would induce the presently observed increase in
striatal DRD2/3 availability for a number of reasons. First,
smoking a regular cigarette, which induces acute dopamine
release, resulted in a significant decrease of striatal DRD2/3
receptors particularly in ventral parts of the striatum (Brody
et al., 2006). Second, the present study showed that increase
in striatal DRD2/3 availability persists up to 2 weeks after
varenicline discontinuation. Third, the studies by Ericson
et al. (2009) and Rollema et al. (2007) measured DA release
extracellular using in-vivo microdialysis, while ex-vivo
storage phosphor imaging measures DRD2/3 binding at the
synaptic level (Schiffer et al., 2006). Finally, rats treated
with several doses of varenicline had similar effects on
DRD2/3 binding in the dorsal and ventral striatum while it
was recently demonstrated that the effects of varenicline
and smoking on the dopaminergic system are most likely
mediated predominantly via α4β2 nAChRs in the VTA (Brody
et al., 2006; Reperant et al., 2010). Instead, it is conceivable
that long-term exposure to varenicline could cause reduced
functioning of the DAergic system, leading to a decrease in
synaptic DA and consequently to an upregulation of striatal
DRD2/3, which are located predominantly postsynaptically.
Alternatively, but speculative, the increase in DRD2/3
availability after chronic varenicline treatment might
be due to effects of varenicline on possible molecular
pathways involved directly in the expression of DRD2/3.
Like most G-protein-coupled receptors, DRD2/3 expression is
regulated by kinases and arrestins (Ito et al., 1999; Kim
et al., 2001). However, to the best of our knowledge, the
effects of varenicline on such kinases and arrestins have not
yet been studied.
We were not able to show dose-dependent effects of
varenicline. This might be due to a ceiling effect from the
doses chosen, and therefore, experiments with doses up to
0.5 mg/kg/day should be performed to further assess dose-
dependency. Additionally, in the present study, experiments
were performed in rats not exposed to nicotine. Since
exposure to nicotine may induce dopaminergic hypersensi-
tivity (Novak et al., 2010), future studies on the effects of
varenicline on DRD2/3 receptor availability in nicotine-
dependent and nicotine-abstinent rats may be relevant to
test if one may generalize our present findings.
In humans, acute administration of varenicline does not
alter smoking behaviour at peak-plasma levels (Williams et al.,
2007), indicating the importance of studying the effects of a
longer treatment with varenicline as was done in the current
experiments. The current study showed a clear sustained
effect of varenicline on DRD2/3 availability in the ventral
striatum with similar increases at 1 day (11%), 1 week (13%),
and 2 weeks (12%) following treatment discontinuation. This
observation indicates that chronic administration of
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through neuroadaptation (vide infra).
The main strengths of the present study are that several
dosages of varenicline were tested, the large variation in
post-treatment duration before DRD2/3 availability assess-
ment, and the use of a well-validated assessment procedure.
A limitation of the study with respect of its translational
value is BID administration of varenicline that has a half-life
in rats of about 4 h (Obach et al., 2006). For instance, peak
levels in rat plasma after a single dose of 1 mg/kg s.c.
(Rollema et al., 2009) will be an order of magnitude higher
than steady state human plasma levels after 1 mg BID
(Faessel et al., 2006), while trough levels at night will be
below therapeutic human plasma levels. Another limitation
is that the radioligand IBZM binds with equal affinity to DRD2
and DRD3 (Videbaek et al., 2000). The ventral striatum
expresses more DRD3 compared to DRD2 than the dorsal
striatum, which is true both for rat and human brain (Booze
and Wallace, 1995; Murray et al., 1994). Since we presently
show different temporal and dosing effects of varenicline for
the dorsal and more ventral parts of the striatum, it is
tempting to speculate that varenicline may induce different
effects on the expression of DRD2 vs DRD3. However, further
studies using selective tracers for DRD2 and DRD3 are
necessary to test this hypothesis.
Finally, we would like to note that imaging studies in drug-
dependent subjects have shown a decrease of about 15% in
striatal DRD2/3 receptor binding in cocaine-dependent
patients compared to controls (Martinez et al., 2004, 2009).
As varenicline resulted in a higher DRD2/3 receptor avail-
ability by about 13% in dorsal and 11% in nucleus accumbens in
rats compared to control rats, and it may have the potential
to normalize decreased DRD2/3 availability in drug or
nicotine dependence. Therefore, we propose future studies
in drug-addicted rats or mice addressing the potential of
varenicline to normalize DRD2/3 availability in drug-addicted
study populations. Moreover, the present study was per-
formed in genetically identical rats. The study by Noble et al.
(1991) showed decreased DRD2 receptors in brains of
alcoholics only when carrying the DRD2 A1 allele. Therefore,
further human studies on the mechanisms of action of
varenicline should take into account potential effects of
genes for DRD2/3 receptors.
In conclusion, administration of varenicline resulted in a
significantly higher striatal DRD2/3 availability in rats
compared to control rats and these effects are long-lasting.
Our findings support the potential of partial nAChR agonists,
such as varenicline, in the treatment of populations with low
DRD2/3 availability, including drug-dependent patients
other than smokers, possibly extending to other reward
deficiency syndromes like obesity and other impulsive and
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